Dynogen’s strategy is to seek U.S. and international patent protection for novel compositions, chemical analogs, formulations, methods of treatment and other commercially relevant innovations related to our product candidates and preclinical assets. 

Our patent portfolio includes the following issued U.S. patents and published U.S. patent applications.

Dynogen’s Issued U.S. Patents
(Please Note: larger PDF files might take a moment to download)

Patent No.	Title	Product
7,223,754	Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders	Preclinical Asset
7,220,748	Use of 4-(2-flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for treating of urinary incontinence	DDP225
7,125,848	Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators	Preclinical Asset
7,115,606	Method of treating lower urinary tract disorders	DDP225
7,094,786	Method of treating nausea, vomiting, retching or any combination thereof	DDP225
7,084,116	Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators	Preclinical Asset
7,041,704	Methods of treating gastrointestinal tract disorders using sodium channel modulators	Preclinical Asset
6,967,207	Preventive or therapeutic agents for gastric or esophageal regurgitation	DDP733
6,846,823	Method of treating lower urinary tract disorders	DDP225
5,352,685	Thieno[3,2-B]pyridine derivatives	DDP733
Dynogen’s Published U.S. Patent Applications (Please Note: larger PDF files might take a moment to download)
Publication No.	Title	Product
20080085916	Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators	DDP200
20070254899	Soluble salts of thieno[2,3-D] pyrimidine derivatives	DDP225
20070254891	Crystalline forms of 4-(2-fluoro-phenyl)-6-methyl-2-(piperazin-1-YL)thieno[2,3-D]pyrimidine	DDP225
20070105785	Methods of treating non-inflammatory gastrointestinal tract disorders using Cav 2.2 subunit calcium channel modulators	Preclinical Asset
20070066597	Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders	Preclinical Asset
20070010543	Compositions and methods for treating gastrointestinal hypomotility and associated disorders	DDP733
20070004770	Preventive agent/remedial agent for constipation predominant IBS	DDP733
20060293309	Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors	Preclinical Asset
20060281781	Preventive and therapeutic medicament for gastroesophageal reflux disease	DDP733
20060276542	Methods for treating functional bowel disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators	DDP200
20060264509	Methods for treating pain using smooth muscle modulators and alpha2delta subunit calcium channel modulators	DDP200
20060234939	Methods of using ziconotide to treat overactive bladder	Preclinical Asset
20060217391	Method of treating functional bowel disorders	DDP225
20060189648	Compositions useful for increasing lower esophageal sphincter pressure	DDP733
20060167005	New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-D] pyrimidine	DDP225
20050282859	Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders	Preclinical Asset
20050272719	Method for inhibiting detrusor muscle overactivity	DDP225
20050239890	Methods for decreasing detrusor muscle overactivity	DDP200
20050239792	4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-D] pyrimidine in the treatment of functional bowel disorder	DDP225
20050228049	Methods for decreasing detrusor muscle overactivity	DDP200
20050222162	Use of 4-(2-flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidine for treating of urinary incontinence	DDP225
20050203190	Methods of treating gastrointestinal tract disorders using sodium channel modulators	Preclinical Asset
20050192270	Methods of decreasing intestinal motility	DDP225
20050148587	Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders	Preclinical Asset
20050113421	Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders	Preclinical Asset
20050107353	Methods of treating lower urinary tract disorders using losigamone	Preclinical Asset
20050059704	Compositions useful for treating gastrointestinal motility disorders	DDP733
20050054725	Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators	DDP200
20050032780	Method of treating functional bowel disorders	DDP225
20050026909	Method of treating lower urinary tract disorders	DDP225
20050026835	Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators	Preclinical Asset
20050020577	Method of treating lower urinary tract disorders	DDP225
20040259862	Method of treating functional bowel disorders	DDP225
20040254172	Method of treating nausea, vomiting, retching or any combination thereof	DDP225
20040254171	Method of treating nausea, vomiting, retching or any combination thereof	DDP225
20040254170	Method of treating functional bowel disorders	DDP225
20040254168	Method of treating functional bowel disorders	DDP225
20040248979	Method of treating lower urinary tract disorders	Preclinical Asset
20040213842	Methods of treating gastrointestinal tract disorders using sodium channel modulators	Preclinical Asset
20040209960	Methods of treating lower urinary tract disorders using sodium channel modulators	Preclinical Asset
20040209869	Method of treating lower urinary tract disorders	DDP225
20040198822	Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators	DDP200
20040198775	Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators	Preclinical Asset
20040192730	Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction	Preclinical Asset
20040147510	Method of treating nausea, vomiting, retching or any combination thereof	DDP225
20040147509	Method of treating functional bowel disorders	DDP225
20040142034	Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators	DDP200
20040048874	New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-D] pyrimidine	DDP225
20030130304	Preventive or therapeutic agents for gastric or esophageal regurgitation	DDP733

Back to Top